A drug trial that worked too well to continue
Praxis stopped its Phase 2 epilepsy trial early because the drug was working — a rare signal. Relutrigine could hit $650M in peak US sales. And the company has an essential tremor drug heading to the FDA with $2.5B+ potential. Two pipeline wins in one day.
image from grok
Praxis Precision Medicines' Phase 2 EMBOLD trial for relutrigine was stopped early after an independent data monitoring board recommended discontinuation for efficacy, a rare structural signal in drug development indicating compelling evidence of benefit. The sodium channel inhibitor targets persistent currents implicated in severe developmental epileptic encephalopathies linked to SCN8A and SCN2A mutations in children, with prior cohorts showing tolerability and robust motor seizure improvements. Full data will be presented at the American Epilepsy Society conference in December, and the company has an FDA meeting scheduled to discuss the regulatory path forward.
- •Stopping a trial early for efficacy is uncommon and structurally significant — independent monitors determined that continuing placebo would be unethical, signaling a different caliber of evidence than typical positive readouts
- •Relutrigine modulates sodium channels by inhibiting persistent currents, a mechanism Praxis identifies as a major driver of symptoms in severe developmental epilepsies, with biomarker changes and motor seizure improvements seen in earlier cohorts
- •Truist Securities projects $650M peak U.S. sales by 2037 for the SCN2A/SCN8A indication alone, with potential for higher revenue if broader DEE labeling is obtained
